Tuberculosis Vaccine Accelerator Council

Tuberculosis Vaccine Accelerator Council

Nana Kofi Acquah / Blink Media
© Credits

About us

In January 2023, WHO’s Director-General announced plans to establish a TB vaccine accelerator Council to facilitate the development, testing, authorization, and use of new TB vaccines, drawing on lessons learned from the response to the COVID-19 pandemic. The establishment meeting of the Council took place on 20 September 2023, on the occasion of the 78th session of the United Nations General Assembly, in the lead up to the Second United Nations High-level Meeting on TB. 

The Council is anticipated to work in multiple ways. These include

  1. identifying needs for, and types of innovative sustainable financial solutions, as well as partnerships between the public, private and philanthropic sectors that can expedite the translation of science into TB vaccines, and ensure their equitable access once available;
  2. identifying market solutions to incentivize TB vaccine development, and to ensure that the R&D ecosystem is positioned to rapidly manufacture and distribute vaccines equitably and at scale, once they are available; and
  3. advocating with decision makers in the public, private, philanthropy and other relevant sectors to strengthen commitment and concerted action to develop and expand access to novel effective TB vaccines, including through political platforms such as the African Union, ASEAN, BRICS, G20, G7 and others.


Participation

The Council will have multiple platforms, the highest level being a Ministerial Board. Another high-level strategic body, a Principal Group will engage senior leadership from financing organizations, philanthropy, public health agencies, relevant partnerships and international agencies and representative of people affected by TB. The Members of the Ministerial Board and Principal Group will serve on a rotating basis, for a term of two years.

Other stakeholders, including research organizations, private sector, scientist, regulators, civil society, and others will be engaged through subsidiary bodies. For more information, see the "architecture of the Council".

Status

The TB vaccine accelerator council is a WHO initiative, an informal voluntary network to exchange views, share information, and enhance technical and political co-operation. It is not a distinct legal entity, and it derives its legal status from WHO. Thus, it shall be administered by WHO, which provides its Secretariat. 

Members of the Ministerial Board

Minister of Health, Brazil (Co-chair)

Minister of Health, Indonesia (Co-chair)

Minister of Social Affairs and Health, France

Cabinet Secretary for Health, Kenya

Minister of Health, Viet Nam

Federal Minister of National Health Services, Regulations and Coordination, Pakistan

Minister of Health, South Africa

Secretary of Health, Philippines

National Institutes of Health, United States of America

Members of the Principal Group

Dr Akinwumi Adesina

President, African Development Bank Group

Dr Trevor Mundel

President of Global Health, Bill and Melinda Gates Foundation

Ms Nadia Calvino

President, European Investment Bank

Dr Juan Pablo Uribe

Global Director for Health, Nutrition & Population and the Global Financing Facility, World Bank

Dr Sania Nishtar

Chief Executive Officer, Gavi, the Vaccine Alliance

Mr Peter Sands

Executive Director, Global Fund

Dr Philippe Duneton

Executive Director, Unitaid

Dr John-Arne Røttingen

Chief Executive Officer, Wellcome Trust

Dr Lucica Ditiu

Executive Director, Stop TB Partnership

Mike Frick

Co-Director of Tuberculosis Project, Treatment Action Group

Publications

All →
Global tuberculosis report 2024

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis...

An investment case for new tuberculosis vaccines

This document summarizes the results of the WHO-commissioned full value proposition for new tuberculosis (TB) vaccines. The assessment was commissioned...

A Global Strategy for tuberculosis research and innovation

The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation,...

WHO Preferred Product Characteristics  for New Tuberculosis Vaccine

The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment...

Progress update report

The update charts progress achieved by the TB Vaccine Accelerator Council and its Secretariat between November 2024 and February 2025.
The update charts progress achieved by the TB Vaccine Accelerator Council and its Secretariat between May and October 2024.